Trace Biosciences Inc.
Beaverton, OR
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1800 NW 167th Pl #160, Beaverton, OR 97006, USA
- Website
- trace-bio.com
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $3,619,794 |
| FY2023 | $599,180 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| The purpose of this modification is to: a. Change the contracting office from NIH NCI to arpa-H B. Update buyer and… | National Institutes of Health | $4,218,974 |
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Oregon Health & Science University | R01CA303975 | $29,936 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Optosurgical, LLC | Columbia, MD | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Mtti | West Chester, PA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Virogenomics Biodevelopment, Inc. | Tigard, OR | — |
| Unandup, LLC | St. Louis, MO | 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing |
| Pyramid Technical Consultants, Inc. | Waltham, MA | 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing |
About the company
Trace Biosciences Inc., a small-business for-profit company based in Beaverton, Oregon, develops near-infrared fluorescent imaging agents and intra-operative contrast reagents for surgical and diagnostic applications, operating exclusively as a prime recipient on federal research grants and Small Business Innovation Research (SBIR) contracts with the National Institutes of Health.
Trace's federal footprint is entirely grant and SBIR research funding from within the Department of Health and Human Services. The company holds a $4.2 million firm fixed price SBIR Phase II contract (awarded September 2023, set aside for total small businesses, completion September 2027) with the Advanced Research Projects Agency for Health for development of intra-operative contrast agents under ARPA-H SBIR Topic 04. Trace is also recipient of a $448 thousand Project Grant from the National Institute of Neurological Disorders and Stroke (awarded September 2026, completion August 2027) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) focused on molecular imaging agents for detecting myelin loss in demyelinating diseases including multiple sclerosis and Charcot-Marie-Tooth disease. Prior grant work includes a Project Grant from the National Cancer Institute awarded June 2023 for two-color near-infrared fluorescence guided surgery tools enabling simultaneous cancer margin and nerve visualization during head and neck squamous cell carcinoma resection. All work is performed in Beaverton, Oregon. Trace operates as prime on 100% of its four total awards; the company has no sub-award footprint.
Customer concentration is absolute: all four awards fund National Institutes of Health programs. The National Cancer Institute and the National Institute of Neurological Disorders and Stroke account for three of the four awards. Two awards (combined potential value $4.2 million) reach ultimate completion within the next twenty-four months and face recompete exposure.
Service Contract Inventory data shows SCI-reported invoicing of $1.5 million in FY2023–FY2025, with a spike to $1.4 million in FY2025 across 3.0 FTEs on prime records. FY2023 carried $100 thousand across 0.3 FTEs, with no SCI-reportable activity in FY2024. Trace delivers federal services without subcontractor engagement (0% sub-hours share across SCI-reportable prime contracts) and prices consistently at a median government-paid rate of $194.66 per hour across SCI records. The SCI dataset captures a portion of Trace's federal services activity and does not reflect total revenue or full workforce; the company's primary federal revenue stream is research grants and SBIR contracts, not services-contract invoicing.
Quick answers
Is Trace Biosciences Inc. registered in SAM.gov?
Yes. Trace Biosciences Inc.'s SAM.gov registration is active through September 4, 2027.
What is Trace Biosciences Inc.'s CAGE code?
Trace Biosciences Inc.'s CAGE code is 9HEB7, and its Unique Entity ID (UEI) is YGDTEJXJC9G8.
How much has Trace Biosciences Inc. received in federal contracts?
Federal contracts obligated $4,218,974 to Trace Biosciences Inc. in fiscal years 2023 through 2027.
What is Trace Biosciences Inc.'s most recent federal award?
Trace Biosciences Inc.'s most recent federal grant award is Molecular imaging of peripheral and central nervous system myelin (R44NS147800), from National Institute of Neurological Disorders and Stroke (NIH), on September 3, 2026.
On GovTribe
See Trace Biosciences Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors